Medco Health Solutions says it expects a generic version of the blockbuster Bristol-Myers Squibb and Sanofi-Aventis blood thinner Plavix to become available in the United States this year. The ...

PARIS/LONDON (Reuters) - French drugmaker Sanofi-Aventis is preparing to sell its own generic version of the blockbuster heart medicine Plavix in France, a company spokesman said on Monday. Plavix, ...

News of the expanded indication comes during a showdown between the marketer/manufacturer of the drug, Bristol-Myers Squibb (BMS)/Sanofi-Aventis, and Canadian drug company Apotex, which started ...

ZURICH, Aug 6 (Reuters) - Novartis AG will sell a generic version of Sanofi-Aventis SA's Plavix blood-thinner at a discount of about 25 percent in Germany, it said on Wednesday. Novartis unit Hexal ...

Bristol-Myers Squibb said generic competition on its biggest drug, Plavix, hamstrung third-quarter earnings, while a federal probe expanded to determine whether an ill-fated deal to protect the Plavix ...

Shares of Bristol-Myers Squibb Co. sank more than 6 percent Tuesday as a generic drug maker disclosed it has begun selling a cheaper version of the big pharmaceutical company’s best-selling drug ...

Sanofi-Aventis and Bristol-Myers Squibb Co. are facing generic competition in the U.S. for their top-selling Plavix blood-thinning pill five years earlier than planned. Apotex Inc., a closely held ...

TRENTON, N.J. (AP) The first generic competition to Bristol-Myers Squibb Co.'s top-selling drug, blockbuster blood thinner Plavix, has slashed sales as expected, dragging down the drugmaker's ...

Plavix is also given to those who have unstable angina or peripheral artery disease. Using Plavix in combination with aspirin may be more effective in preventing another heart attack, but this will ...

Bristol-Myers Squibb Co. and Sanofi-Aventis on Thursday won a bid to stop Apotex Inc. from selling its cheaper generic version of the Plavix heart pill, the world’s second-biggest-selling medicine.

In addition, there were no significant differences between the drug groups in the percent of patients who died or were hospitalized for any reason; had a stroke or transient ischemic attack ; or who ...